Super Stock Screener stock portfolios are baskets of Strong Buy stocks designed to outperform their respective benchmarks with low volatility.
Microsoft(NASDAQ:MSFT) is a tech juggernaut with a chorus of bullish analysts. The stock is rated as a “Strong Buy” with a projected 18% upside. While the average price target indicates the stock has plenty of room to run, some analysts are even more bullish. The highest price target ...
according to theTipRanks database, both stocks are also rated as Strong Buys by the analyst consensus. Let’s see what’s driving the unanimous praise from
There are 44 Wall Street firms covering BABA shares, and seven have given the e-commerce giant a “strong buy” rating, while 30 have rated its shares a “buy.” Baidu (BIDU) Baidu(NASDAQ:BIDU) is another Chinese tech giant whose share price has reeled from politics and a slowing ...
It turns out that both are rated as Strong Buys by the analyst consensus. Let’s find out why. Revance Therapeutics (RVNC) The first Goldman Sachs-backed company we’ll look at is Revance Therapeutics, a biotech company that specializes in developing innovative treatments for various medical ...
Here are the highest-rated stocks from Warren Buffett's portfolio, according to analysts. When it comes to choosing a role model, investors can't do much better thanBerkshire Hathaway Inc.(ticker:BRK.A,BRK.B) CEO and Wall Street icon Warren Buffett. There are countless books, articles...
According to TipRanks, the world’s biggest database of analysts and research, both of these stocks are also rated as ‘Strong Buys’ by the analyst consensus. Let’s see why they are drawing plaudits across the board. V2X, Inc. (VVX) The world is a complex place, and the ...
TipRanks consensus rating:Strong Buy Among all 30 Dow stocks,Visa(V, $160.16) is the best-rated blue chip with 16 consecutive buy ratings over the past three months. The rave reviews include a reiterated “Buy” rating from five-star Nomura analyst Bill Carcache, who calls V stock his to...
On a year-to-date basis, POWI has rallied 39.9% to close Friday’s session at $69.18. During the past six months, POWI has soared 25.1%. It’s no surprise that POWI is rated “Strong Buy” in our POWR Ratings system. It also has an “A” for Trade Grade, Buy & Hold Grade, ...
unmet patient needs. Yesterday,TD Cowen analyst Ritu Baralmaintained a Buy rating on the stock with a price target of $78. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of over 96%....